Get the Stockscreener App
1.845
1.37%
0.025
After Hours:
1.96
0.115
+6.23%
Entera Bio Ltd stock is traded at $1.845, with a volume of 18,534.
It is up +1.37% in the last 24 hours and down -14.98% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
See More
Previous Close:
$1.82
Open:
$1.81
24h Volume:
18,534
Relative Volume:
0.41
Market Cap:
$83.86M
Revenue:
$134.00K
Net Income/Loss:
$-9.93M
P/E Ratio:
-5.4265
EPS:
-0.34
Net Cash Flow:
$-6.72M
1W Performance:
-5.38%
1M Performance:
-14.98%
6M Performance:
+12.50%
1Y Performance:
-20.13%
1-Day Range:
$1.80
$1.86
1-Week Range:
$1.69
$1.98
52-Week Range:
$1.41
$2.79
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.845 | 89.09M | 134.00K | -9.93M | -6.72M | -0.34 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Financial Comparison: Entera Bio (NASDAQ:ENTX) versus Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Entera Bio Reports Q1 2025 Financial Results and Strategic Developments - TipRanks
Entera Bio Reports Q1 2025 Results and Strategic Updates - TipRanks
Entera Bio Ltd. Reports Q1 2025 Financial Results and Business Updates, Advances Oral Osteoporosis Treatment and Partnerships - Nasdaq
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Entera Bio Ltd expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Entera Bio (ENTX) to Release Earnings on Friday - Defense World
Entera Bio (NASDAQ:ENTX) Trading Up 5.6% – Time to Buy? - Defense World
Entera Bio reports positive phase 2 results for osteoporosis treatment By Investing.com - Investing.com South Africa
Entera Bio reports positive phase 2 results for osteoporosis treatment - Investing.com
Game-Changing Oral Osteoporosis Treatment Matches Injectable Efficacy in Clinical Trial - Stock Titan
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with OsteoporosisHighlighted as Oral Presentation at WCO-IOF ESCEO - GlobeNewswire
Entera Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Entera Bio Reports Transformative Year in 2024 - TipRanks
Entera Bio Ltd. (ENTX) reports earnings - Quartz
Entera Bio Announces 2024 Financial Results and Updates - TipRanks
Entera Bio's Breakthrough: Oral Peptide Programs Show Promise as 2024 Results Reveal $21M War Chest - Stock Titan
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Entera Bio’s (ENTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld MedTech
OPKO and Entera team up on oral obesity candidate - The Pharma Letter
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
OPKO and Entera partner to develop obesity pill -March 17, 2025 at 08:54 am EDT - Marketscreener.com
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement - StreetInsider
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
Entera Bio (ENTX) Expected to Announce Quarterly Earnings on Friday - Defense World
Entera Bio Ltd. to Host Earnings Call - ACCESS Newswire
Entera Bio to Participate in Upcoming Events - GlobeNewswire
Can Entera Bio's Upcoming Scientific Data Reshape Oral Peptide Therapy? Major Conference Schedule Revealed - Stock Titan
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskel - The Manila Times
Could This Oral Osteoporosis Treatment Replace Daily Injections? Phase 2 Data Reveals Promising Results - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 31.6% in January - MarketBeat
US Penny Stocks: 3 Picks With Market Caps Over $60M - Yahoo Finance
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
145,843 Shares in Entera Bio Ltd. (NASDAQ:ENTX) Acquired by Perigon Wealth Management LLC - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 23.1% in January - MarketBeat
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):